Alchemab Therapeutics Ltd of the UK has raised £60 million in a Series A round to advance a drug discovery platform that involves identifying naturally protective antibodies in individuals who show unexpected resistance to disease. The financing round was led by RA Capital Management, with participation from five other investors including SV Health Investors and the Dementia Discovery Fund.
